TITLE

Prognostic factors in patients with advanced hepatocellular carcinoma receiving hepatic arterial infusion chemotherapy

AUTHOR(S)
Yamasaki, Takahiro; Kimura, Teruaki; Kurokawa, Fumie; Aoyama, Kouji; Ishikawa, Tsuyoshi; Tajima, Kunihiko; Yokoyama, Yuichiro; Takami, Taro; Omori, Kaoru; Kawaguchi, Kotaro; Tsuchiya, Masako; Terai, Shuji; Sakaida, Isao; Okita, Kiwamu
PUB. DATE
January 2005
SOURCE
Journal of Gastroenterology;2005, Vol. 40 Issue 1, p70
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background. The prognosis of patients with advanced hepatocellular carcinoma (HCC) is poor. We aimed to clarify the prognostic factors in patients with advanced HCC receiving hepatic arterial infusion chemotherapy (HAIC). Methods. Forty-four HCC patients were treated with HAIC, using low-dose cisplatin (CDDP) and 5-fluorouracil (5-FIJ) with/without leucovorin (or isovorin). Of these 44 patients, 15 received low-dose (CDDP) and 5-FIJ, and 29 received low-dose CDDP, 5-FIJ, and leucovorin or isovorin. Prognostic factors were evaluated by univariate and multivariate analyses of patient and disease characteristics. Results. Of all patients, 5 and 12 patients respectively, exhibited a complete response (CR) and a partial response (PR) (response rate, 38%). rme response rate (48.3%) in the low-dose CDDP and 5-FIJ with leucovorin/isovorin group was significantly better than that (20%) in the low-dose CI)I)P and 5-FIJ group (P = 0.002). The 1-, 2-, 3-, and 5-year cumulative survival rates of the 44 patients were 39%, 18%, 12%, and 9%, respectively. The regimen using low-dose CDDP and 5-FU with leucovorin/isovorin tended to improve survival rates (P = 0.097). Univariate and multivariate analyses showed the same variables-the Child-Pugh score (P = 0.013, P 0.018), (x-fetoprotein (AFP) level (P 0.010, P = 0.009), and therapeutic effect after HAIC (P = 0.003, P 0.01), respectively, to he significant prognostic factors. Conclusions. Patients who had advanced HCC with favorable hepatic reserve capacity and a lower AFP level were suitable candidates for HAIC. Moreover, the regimen using low-dose CDDP and 5-FIJ with leucovorin/isovorin may he suitable for advanced HCC patients, because of the improvement in the response rate and survival compared with the low-dose CDDP and 5-FU regimen without leucovorin/isovorin.
ACCESSION #
15932817

 

Related Articles

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics